source
- Novartis launches Phase 3 trial of IL-6 antibody to test cardiovascular benefit despite Novo's setbackNovartis announced it will begin a Phase 3 study evaluating its anti-IL-6 monoclonal antibody in patients at high cardiovascular risk. The trial aims to determine whether reducing inflammation thr…
- FDA approves Mimrylo, first hepcidin-mimicking drug for polycythemia veraThe U.S. Food and Drug Administration announced approval of Mimrylo (rusfertide) for adult patients with polycythemia vera, a rare blood disorder that causes excess red blood cells. The drug mimic…